Recently, it made its first entry into oligonucleotides, a move triggered by a “very rich pipeline​.”

“There is not enough capacity to respond to the market needs​,” Ayoub said. “So, CordenPharma has decided to help the market close that gap​.”

Ayoub described Oligonucleotide APIs as “a central piece that was missing​.” Though, “we are closing that gap now​,” he said, adding that the only piece now missing is upstream processing – which will be added in two phases expected to be finalized by the fourth quarter of 2017.

The company is also investing in aseptic filling and adding two high-speed lines – one for prefilled syringes and another for vials.

“We are also adding Lyophilization capabilities​,” added Ayoub, “All of this will be completed before the end of the year​.”